Market Overview

Vetr Top Raters Upgrade Mannkind To 4.5-Star Stock

Share:
Related MNKD
MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind
Earnings Scheduled For November 9, 2016

Shares of MannKind Corporation (NASDAQ: MNKD) have lost nearly 50 percent of its value since the start of 2016 and are lower by more than 85 percent over the past year.

Despite the large losses over the past year, the Vetr crowd is bullish on the stock's outlook as its rating was upgraded to 4.5-stars out of a possible 5. In fact, shares of MannKind have risen to $0.78 since the prior rating of 3.0-stars was issued just 5 days.

Related link: Here's how crowdsourced ratings can beat the market.

In addition to an upgrade which signals a bullish outlook, 81 percent of the crowd's ratings are bullish and a crowd sourced price target of $0.90 implies a potential upside of more than 27 percent.

"This former $7 stock has been crushed, to some degree with reason but under $1 a bit much," TONY CALATAYUD, a member of the Vetr crowd argued in defense of MannKind's stock. "Should see some nice percentage gains by end of Q1. Not a medium or long term hold. In and out in 90 days."

Latest Ratings for MNKD

DateFirmActionFromTo
Nov 2015Griffin SecuritiesDowngradesBuyNeutral
Nov 2015RBC CapitalDowngradesOutperformUnderperform
Sep 2015PiperJaffrayDowngradesNeutralUnderweight

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Crowd SourcingAnalyst Color Biotech Long Ideas Crowdsourcing Analyst Ratings Trading Ideas General

 

Related Articles (MNKD)

View Comments and Join the Discussion!